エボラウイルスワクチン市場：ウイルス株、流通チャネル、エンドユーザー、地域別、2026～2032年

エボラウイルスワクチン市場の評価-2026～2032年

エボラウイルスワクチンの世界の流行増加が市場成長を促進エボラウイルスワクチン市場は、2024年には1,143万米ドルと評価され、2032年にはCAGR 32.80%で9,176万米ドルに成長すると予測されています。

成長軌道は市場力学の上昇傾向を示しています。予測される拡大は、予測される期間における力強い成長率を指し示しています。2026～2032年にかけてのCAGRは32.80%で成長します。

エボラウイルスワクチン市場定義/概要

一般にエボラ出血熱として知られるエボラは、エボラウイルス属に属する致死性のウイルス疾患の1つです。エボラは近年、人類にとって大きな脅威となっています。通常、このウイルスは動物を介してヒトに感染します。

エボラ出血熱は、血液凝固によって引き起こされる世界で最も致命的な病気の一つです。最も典型的にはアフリカ諸国で発生します。体内の細い血管から血液が流れ出て内出血を起こす凝固異常のため、出血熱ウイルスとして特徴づけられます。エボラウイルス属のウイルスの感染によって引き起こされます。

エボラウイルス病（EVD）は、エボラウイルスによって引き起こされるヒトの重篤で致死率の高い病気です。エボラワクチンの市場は、特に2014～2016年にかけて西アフリカで深刻なエボラ出血熱が発生し、集団発生を管理し住民を保護するための効果的なワクチンの重要な必要性が強調された後、大きく成長しました。

エボラウイルスワクチン市場は、エボラ出血熱の将来の流行を予防・制御するための世界の取り組みの重要な一部です。政府、製薬企業、学術機関、非営利団体の協力により、エボラウイルスワクチンの開発、製造能力、世界の流通が推進されています。市場課題としては、特に低所得国におけるワクチンの価格と入手しやすさの確保、ワクチン接種のためらいや偽情報への対処、長期的な製造・供給ネットワークの維持などが挙げられます。

世界のエボラウイルスワクチン市場とは？

国立医療図書館によると、エボラ出血熱の発生は1976年です。スーダン南部とコンゴ民主共和国北部を襲い、6月から9月までの約4ヶ月間続き、死亡率はそれぞれ53％と88.1％でした。後に同定され、最初の流行の責任を問われた2つのウイルスは、スーダン・エボラウイルスとザイール・エボラウイルスでした。

エボラウイルスワクチン市場の成長と開拓。最も重要な要件は、エボラ出血熱の流行による公衆衛生の危機に対処することです。エボラウイルス病（EVD）が人体に及ぼす破壊的な影響や、広範囲に感染する可能性から、効果的な予防対策の必要性が浮き彫りになっています。

エボラウイルスワクチン市場の拡大・開拓により、エボラウイルスワクチンが世界保健安全保障の取り組みに不可欠な要素であることが確立されます。科学的、財政的、規制的、地政学的な力の組み合わせが、強力な推進力となっています。

エボラウイルスワクチン市場が直面する課題とは？

現在のエボラワクチンの需要は、そのほとんどがアウトブレイクへの対応に追われています。アウトブレイクの予期せぬ性質や、医療資源が限られている中低所得国に疾病が集中しているなどの変数があるため、ワクチン接種プログラムが広く実施されるには至っていないです。

予防接種の開発・製造には多額の費用がかかります。その結果、ワクチンの価格設定が高くなり、資源に乏しく、伝染病が最も流行しやすい地域での入手可能性や利用しやすさが制限される可能性があります。

ロジスティクスの課題には、インフラの少ない遠隔地でのワクチンの配布や保管が含まれます。こうした予防接種に必要なコールドチェーン条件をサプライチェーンに沿って維持することは、新たなレベルの複雑さをもたらします。

エボラウイルスワクチンに対する厳しい規制上の許認可は、市場拡大を大きく阻害する可能性があります。規制要件は新しい予防接種の発売を遅らせ、新規事業の市場参入を妨げる可能性があります。ワクチン開発と商業化のための承認時間と費用の増大は、市場の成長を制限する可能性があります。経営資源が限られた小規模企業は、包括的な臨床検査、安全性評価、製造要件などを要求する厳しい法律への対応に苦慮する可能性があります。規制上の障壁がエボラウイルスワクチンの商業化と入手を妨げ、市場成長を阻害する可能性があります。

目次

第1章 世界のエボラウイルスワクチン市場の導入

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界のエボラウイルスワクチン市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 エボラウイルスワクチンの世界市場：ウイルス株別

• 概要
• 組み換え水疱性口内炎ウイルス
• チンパンジーアデノウイルス3型
• アデノウイルス血清型26

第6章 エボラウイルスワクチンの世界市場：流通チャネル別

• 概要
• 病院と小売薬局
• オンライン薬局
• 政府供給業者
• その他

第7章 エボラウイルスワクチンの世界市場：エンドユーザー別

• 概要
• 病院
• 在宅医療
• 専門クリニック
• 外来手術センター
• その他

第8章 エボラウイルスワクチンの世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他のアジア太平洋
• その他
  • ラテンアメリカ
  • 中東・アフリカ

第9章 世界のエボラウイルスワクチン市場の競合情勢

• 概要
• 各社の市場ランキング
• 主要開発戦略

第10章 企業プロファイル

• Sarepta Therapeutics
• Mapp Biopharmaceutical
• Regeneron Pharmaceuticals, Inc.
• GlaxoSmithKline plc.
• Novavax, Inc.
• GeoVax
• Tekmira Pharmaceuticals
• NewLink Genetics Corporation
• Bavarian Nordic
• Merck & Co., Inc.

第11章 主要開発

• 製品上市/開発
• 合併と買収
• 事業拡大
• パートナーシップと提携

第12章 付録

• 関連調査

Ebola Virus Vaccine Market Valuation - 2026-2032

The rising prevalence of Ebola Virus Vaccine illnesses worldwide will fuel market growth. The Ebola Virus Vaccine Market was valued at USD 11.43 Million in 2024 and is expected to increase at a 32.80% CAGR to USD 91.76 Million by 2032.

The growth trajectory points to an upward tendency in market dynamics. Anticipated expansion points to strong growth rates in the anticipated period. Overall, the market is primed for tremendous growth the market grows at a CAGR of 32.80% from 2026 to 2032.

Ebola Virus Vaccine Market: Definition/ Overview

Ebola, commonly known as Ebola hemorrhagic fever, is one of the deadly virus illnesses found in the Ebolavirus genus. Ebola has emerged as a huge threat to mankind in recent years. Typically, the virus is transmitted to humans via animals.

Ebola is one of the world's most deadly diseases caused by blood coagulation. It most typically occurs in African countries. It is characterized as a haemorrhagic fever virus because of the coagulation issues that lead to internal bleeding when blood pours from small blood vessels in the body. It is caused by an infection with viruses from the Ebolavirus genus.

Ebola virus disease (EVD) is a serious and frequently fatal sickness in humans caused by the Ebola virus. The market for Ebola vaccines has grown significantly, particularly after the serious Ebola outbreak in West Africa from 2014 to 2016, which emphasized the critical need for effective vaccines to manage outbreaks and protect populations.

The Ebola virus vaccine market is an important part of global efforts to prevent and control future outbreaks of the illness. Collaborations among governments, pharmaceutical corporations, academic institutions, and non-profit groups are driving Ebola virus vaccine development, manufacturing capacity and global distribution. Market challenges include assuring vaccine price and accessibility, particularly in low-income countries, tackling vaccination hesitancy and disinformation, and maintaining long-term manufacturing and supply networks.

What was the global Outbreaks of Ebola Virus Vaccine Market?

According to the National Library of Medicine, the outbreak occurred in the year 1976. It struck southern Sudan and the northern part of the Democratic Republic of Congo and lasted for about four months, lasting from June to September, with a mortality rate of 53% and 88.1%, respectively. The two viruses that were later identified and held accountable for the first outbreak were Sudan ebolavirus and Zaire ebolavirus.

The growth and development of the Ebola virus vaccine market. The most important requirement is to handle the public health crisis caused by Ebola epidemics. The destructive effects of Ebola virus disease (EVD) on human health, as well as its potential for broad transmission, highlight the need for effective preventive measures.

The expansion and development of the Ebola virus vaccine market, establishing it as an essential component of global health security efforts. The combination of scientific, financial, regulatory, and geopolitical forces emphasizes the strong drivers propelling.

What are the Challenges Faced by the Ebola Virus Vaccine Market?

The current demand for Ebola vaccinations is mostly driven by outbreak response efforts. Widespread vaccination programs have yet to be undertaken due to variables such as the unexpected nature of outbreaks and the concentration of illnesses in low and middle income countries with limited medical resources.

High costs for developing and manufacturing vaccinations are costly operations. This can result in high vaccine pricing, thereby limiting affordability and accessibility in resource-constrained areas most vulnerable to epidemics.

Logistical challenges include distributing and storing vaccines in remote places with little infrastructure. Maintaining the requisite cold chain conditions for these vaccinations along the supply chain adds a new level of complication.

Stringent regulatory licensing for Ebola virus vaccines might severely impede market expansion. Regulatory requirements can slow the launch of new vaccinations and prevent new businesses from entering the market. Increasing approval time and expenses for vaccine development and commercialization may restrict market growth. Small enterprises with limited resources may struggle to comply with tight laws, which require comprehensive clinical trials, safety evaluations, and manufacturing requirements. Regulatory barriers might impede the commercialization and availability of Ebola virus vaccines, hindering market growth.

Category-Wise Acumens

How the Vesicular Stomatitis Virus Platform has emerged in Ebola Virus Vaccine Market?

In the Ebola virus vaccine the vesicular stomatitis virus (rVSV) platform has emerged as a dominant force and is rapidly expanding. The rVSV platform makes use of a genetically modified vesicular stomatitis virus, with the surface glycoprotein replaced by that of the Ebola virus. In clinical trials, this platform showed encouraging findings, including high effectiveness and the potential to induce powerful immune responses against Ebola virus infection.

Accine platforms, such as animal adenovirus type 3 (ChAd3) and adenovirus serotype 26 (Ad26), are also making progress in the sector. ChAd3 and Ad26 vaccines use adenovirus vectors to transmit genetic material encoding Ebola virus antigens, thereby inducing an immune response. These systems have shown efficacy and safety characteristics in clinical trials and are being investigated as potential replacements or complementing vaccines to the rVSV platform.

The Ebola virus vaccine market the rVSV platform presently leading. The ChAd3 and Ad26 platforms are also rapidly expanding and offer intriguing options in the search for effective Ebola virus vaccines. Continued research and development across many vaccine platforms is critical to addressing the complex challenges posed by Ebola virus infection and ensuring the availability of viable vaccines for future outbreaks.

How the Hospitals & Government Suppliers contain the supreme for several reasons for in Ebola Virus Vaccine Market?

The supreme for several reasons for Ebola Virus Vaccine the Hospitals and Government Suppliers this route is dominant for numerous reasons. Ebola outbreaks typically occur in areas with limited access to retail pharmacies. Because of the vaccines particular storage requirements (cold chain maintenance) hospitals and government entities have the facility and competence to handle them properly. Finally, during outbreaks, governments frequently coordinate vaccination programs, making them key distributors.

The Ebola vaccine market is likely to be limited position but online pharmacies are a fast-increasing part of the pharmaceutical industry. The aforementioned cold chain requirements, combined with the fact that Ebola vaccines are typically utilized during outbreaks (rather than for normal injections), make online pharmacies an unsuitable alternative.

How Vaccines and Healthcare Industries are increasing in North America by Ebola Virus Vaccine Market?

The increasing development of vaccines and pharmaceuticals in the healthcare industry, as well as the presence of leading pharmaceutical companies in North America, the market in this region is expected to rise significantly throughout the forecast period.

North America, especially the United States, has a booming pharmaceutical industry distinguished by cutting-edge R&D infrastructure, modern manufacturing capabilities and a favourable regulatory framework. The region is home to several renowned pharmaceutical corporations, including Pfizer, Johnson & Johnson, Merck & Co., and Moderna, among others, which are constantly investing in breakthrough medication discovery and development projects.

North America is expected to benefit from rapid expansion in the healthcare business. The region's premier pharmaceutical businesses, combined with ongoing investments in R&D and technical innovation, will propel healthcare forward and contribute to the region's status as a global pharmaceutical powerhouse.

How the Ebola virus vaccine market Present in Asia-Pacific?

The Ebola virus vaccine market in the Asia Pacific is a complex environment with many elements influencing its development and accessibility. Historically, the region has had less direct exposure to Ebola outbreaks than regions such as Africa, but concerns about the virus's potential spread and the need for preparedness have motivated increased focus on vaccine development and deployment.

The Asia Pacific area is distinguished by country-specific variations in healthcare infrastructure and resources. While some countries have advanced healthcare systems and research capacities, others confront severe challenges such as limited budget, inadequate infrastructure, and a healthcare manpower shortage. These obstacles can stymie vaccine research efforts and restrict access to immunizations in impoverished communities.

Asia Pacific offers chances for innovation and collaboration in the Ebola virus vaccination industry. As the region's healthcare infrastructure and research capacity improve, there is an opportunity for increased investment in vaccine development and distribution. Furthermore, addressing health inequities and ensuring fair access to vaccines will be critical to effectively managing possible Ebola outbreaks throughout Asia Pacific.

Competitive Landscape

The Ebola virus vaccine market industry companies use numerous tactics such as collaborations, acquisitions, mergers, and partnerships to establish a global presence and remain competitive. Please note that the company profile section includes both commercially available drugs and those in clinical development.

The Ebola Virus Vaccine Market study report will provide valuable insight with an emphasis on the global market. The major players in the market include:

Sarepta Therapeutics

Mapp Biopharmaceutical

Regeneron Pharmaceuticals, Inc.

GlaxoSmithKline plc.

Novavax, Inc.

GeoVax

Tekmira Pharmaceuticals

NewLink Genetics Corporation,

Bavarian Nordic

Merck & Co., Inc.

Johnson & Johnson.

Latest Developments

In October 2022, Merck & Co. will manufacture and give an investigational Sudan ebolavirus vaccine to a global non-profit organization's research program in Uganda, which is experiencing an outbreak.

In November 2021, the University of Oxford began phase one of its studies, evaluating the vaccine on human volunteers. In phase one of the studies, 26 participants aged 18 to 55 will get a single dose of the ChAdOx1 biEBOV Ebola vaccine at the university. They will subsequently be studied for six months, with the results expected in the second quarter of 2022.

In July 2020, Johnson & Johnson gained European Commission approval for an Ebola vaccine regimen for the prevention of Ebola Virus disease. The company's plan approval allows for collaboration with the World Health Organization (WHO) on vaccine pre-qualification, resulting in faster registration of its Ebola vaccine in African nations and a stronger market position.

Ebola Virus Vaccine Market, By Category

• Virus Strain:
• Recombinant Vesicular Stomatitis Virus
• Chimpanzee Adeno Virus Type 3
• Adeno Virus Serotype 26
• Distribution Channel:
• Hospital & Retail Pharmacies
• Online Pharmacies
• Government suppliers
• Others
• End User:
• Hospital
• Homecare
• Specialty Clinics
• Ambulatory Surgical Centres
• Medical Center
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL EBOLA VIRUS VACCINE MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL EBOLA VIRUS VACCINE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL EBOLA VIRUS VACCINE MARKET, BY VIRUS STRAIN

• 5.1 Overview
• 5.2 Recombinant Vesicular Stomatitis Virus
• 5.3 Chimpanzee Adeno Virus Type 3
• 5.4 Adeno Virus Serotype 26

6 GLOBAL EBOLA VIRUS VACCINE MARKET, BY DISTRIBUTION CHANNEL

• 6.1 Overview
• 6.2 Hospital & Retail Pharmacies
• 6.3 Online Pharmacies
• 6.4 Government suppliers
• 6.5 Others

7 GLOBAL EBOLA VIRUS VACCINE MARKET, BY END USER

• 7.1 Overview
• 7.2 Hospital
• 7.3 Homecare
• 7.4 Specialty Clinics
• 7.5 Ambulatory Surgical Centres
• 7.6 Others

8 GLOBAL EBOLA VIRUS VACCINE MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East & Africa

9 GLOBAL EBOLA VIRUS VACCINE MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Sarepta Therapeutics
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Mapp Biopharmaceutical
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Regeneron Pharmaceuticals, Inc.
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 GlaxoSmithKline plc.
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Novavax, Inc.
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 GeoVax
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Tekmira Pharmaceuticals
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 NewLink Genetics Corporation
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Bavarian Nordic
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Merck & Co., Inc.
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 Appendix

• 12.1 Related Research